ProCE Banner Activity

DRIVE2Simplify, Part 2: Wk 48 Results From Phase IIb study of Islatravir + Doravirine vs DOR/3TC/TDF in ART-Naive Adults

Slideset Download
Conference Coverage
Virologic suppression maintained in patients who initiated triple therapy with islatravir + DOR + 3TC, achieved virologic suppression, and then switched to 2-drug therapy with islatravir + DOR.

Released: July 29, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner